Heparin Sodium Market is projected to grow with CAGR of 7.9% during the forecast period of 2017 to 2025.In 2017, the Cardioversion of Atrial Fibrillation/Flutter segment generated the highest revenue share in the global heparin sodium market.
Heparin is an anticoagulant that prevents blood from clotting. It does not dissolve the existing blood clots but averts it from expanding and causing serious problems. Heparin finds its major application in various medical processes, owing to its ability to prevent blood from clotting during surgeries, dialysis and transfusions. Patients undergoing surgeries or those that have been subjected to complete bed rest for long period of time are given low doses of heparin, in order to prevent blood clots. Heparin may also be used to diagnose and treat a serious blood condition called disseminated intravascular coagulation.
The major factors driving the market growth are increase in the incidence of thrombosis, rising awareness among the patient population regarding the availability of such treatment options, and rise in government funding towards improving healthcare facilities. However, stringent government regulations might hinder the market growth.
HEPARIN SODIUM MARKET DETERMINANTS-IMPACT ANALYSIS, 2017 Vs. 2022
The global heparin sodium market is segmented on the basis of application and geography. By type, the market is segmented as treatment of venous thromboembolism, pregnancy, cardio version of atrial fibrillation, and others. Geographically, the market is segmented into North America, Europe, China, Japan, India, and Southeast Asia.
HEPARIN SODIUM MARKET REVENUE AND GROWTH RATE, 2017-2022
Some major market players of the sodium heparin market are Shenzhen Hepalink, Bioibérica, Nanjing King-Friend, Pfizer, SPL, Dongcheng Biochemicals, Changzhou Qianhong Bio-Pharma, Changshan Biochemical, Pharma Action, Baxter, Dongying Tiandong Pharmaceutical, Opocrin, Aspen Oss, Xinbai Pharmaceuticals, Yino Pharma Limited, and Sichuan Deebio.
HEPARIN SODIUM MARKET SEGMENTATION
• Treatment of Venous Thromboembolism
• Cardioversion of Atrial Fibrillation/Flutter
• North America
• Southeast Asia
HEPARIN SODIUM MARKET KEY PLAYERS
• Shenzhen Hepalink
• Nanjing King-Friend
• Dongcheng Biochemicals
• Changzhou Qianhong Bio-Pharma
• Changshan Biochemical
• Pharma Action
• Dongying Tiandong Pharmaceutical
• Aspen Oss
• Xinbai Pharmaceuticals
• Yino Pharma Limited
• Sichuan Deebio